INTSbenzinga

Intensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 10, 2025 by benzinga